Preview

Артериальная гипертензия

Расширенный поиск

Илья Клейнер «Портрет Иосифа Бродского». Факторы риска развития фибрилляции предсердий. Современные подходы к лечению

https://doi.org/10.18705/1607-419X-2010-16-4-423-428

Полный текст:

Об авторе

Т. Н. Новикова
Санкт-Петербургская медицинская академия последипломного образования СПб ГУЗ «Городская Покровская больница»
Россия


Список литературы

1. Волков С. Диалоги с Иосифом Бродским. - М.: Независимая газета, 1998. - 328 с.

2.

3. Nieuwlaat R., Capucci A., Camm A.J. et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. - 2005. - Vol. 26, № 22. - P. 2422-2434.

4.

5. Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial // Lancet. - 2000. - Vol. 356, № 9244. - P. 1789-1794.

6.

7. Hohnloser S.H., Crijns H.J., van Eickels M. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 360, № 7. - P. 668-678.

8.

9. Kannel W.B., Abbott R.D., Savage D.D., McNamara F.A. Epidemiologic features of cronic atrial fibrillation: the Framingam study // N. Engl. J. Med. - 1982. - Vol. 306, № 17. - P. 1018-1022.

10.

11. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing for atrial fibrillation: population based-estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8А. - P. 2N-9N.

12.

13. Verdecchia P., Reboldi G.P., Cattobigio R. et al. Atrial fibrillation in hypertension // Hypertension. - 2003. - Vol. 41, № 2. - P. 218-223.

14.

15. Dorian P., Singh B.N. Upstream therapies to prevent atrial fibrillation // Eur. Heart J. - 2008. - Vol. 10 (Suppl. H). - P. H11-H31.

16.

17. Singh B.N., Connolly S.J., Crijns H.J. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter // N. Engl. J. Med. - 2007. - Vol. 357, № 10. - P. 987-999.

18.

19. Hohnloser S.H., Crijns H., van Eickels M. et al. Effect of dronedaron on cardiovascular events in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 360, № 7. - P. 668-678.

20.

21. Camm A.J., Kirchhof P., Lip G.Y.H. et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur. Heart J. - 2010.

22.

23. Davy J.M., Herold M., Hoglund C. et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study // Am. Heart J. - 2008. - Vol. 156, № 3. - P. 527-529.

24.

25. Patel С., Yan G.-X., Peter R., Kowey P.R. Dronedarone // Circulation. - 2009. - Vol. 120, № 7. - P. 636-644.

26.

27. Savelieva I., Camm A.J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches // Europace. - 2008. - Vol. 10, № 6. - P. 647-665.

28.

29. Roy D., Pratt C.M., Torp-Pedersen C. et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial // Circulation. - 2008. - Vol. 117. - P. 1518-1525.

30.

31. Kowey P.R., Dorian P., Mitchell L.B. et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placedo-controlledtrial // Circ. Arrhythm. Electrophysiol. - 2009. - Vol. 2, № 6. - P. 652-659.

32.

33. Goette A., Staack T., Rocken C. et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 6. - P. 1669-1677.

34.

35. Boldt A., Wetzel U., Weigl J. et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease // J. Am. Coll. Cardiol. - 2003. - Vol. 42, № 10. - P. 1785-1792.

36.

37. Doronin S.V., Potapova I.A., Lu Z., Cohen I.S. Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization // J. Biol. Chem. - 2004. - Vol. 279, № 46. - P. 48231-48237.

38.

39. Chen Y.J., Chen Y.C., Tai C.T. et al. Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins // Br. J. Pharmacol. - 2006. - Vol. 147, № 1. - P. 12-22.

40.

41. Nakashima H., Kumagai K., Urata H., Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation // Circulation. - 2000. - Vol. 101, № 22. - P. 2612-2617.

42.

43. Li D., Shinagawa K., Pang L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure // Circulation. - 2001. - Vol. 104, № 21. - P. 2608-2614.

44.

45. Shi Y., Li D., Tardif J. C., Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure // Cardiovasc. Res. - 2002. - Vol. 54, № 2. - P. 456-461.

46.

47. Boldt A., Scholl A., Garbade J. et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation // Basic Res. Cardiol. - 2006. - Vol. 101, № 3. - P. 261-267.

48.

49. von Lewinski D., Kockskamper J., Rubertus S. U. et al. Direct proarrhythmogenic effects of angiotensin II can be suppressed by AT(1) receptor blockade in human atrial myocardium // Eur. J. Heart Fail. - 2008. - Vol. 10, № 12. - P. 1172-1176.

50.

51. Schneider M.P., Hua T.A., Böhm M. et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition. A meta-analysis // J. Am. Coll. Cardiol. - 2010. - Vol. 55, № 21. - P. 2299-2307.

52.

53. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial // Lancet. - 1999. - Vol. 353, № 9153. - P. 611-616.

54.

55. Hansson L., Lindholm L.H., Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients With Hypertension-2 study // Lancet. - 1999. - Vol. 354, № 9192. - P. 1751-1756.

56.

57. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. - 2005. - Vol. 45, № 5. - P. 712-719.

58.

59. Salehian O., Healey J., Stambler B. et al. Impact of ramipril on theincidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study // Am. Heart J. - 2007. - Vol. 154, № 3. - P. 448-453.

60.

61. Schmieder R.E., Kjeldsen S.E., Julius S. et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial // J. Hypertens. - 2008. - Vol. 26, № 3. - P. 403-411.

62.

63. Yusuf S., Teo K., Anderson C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial // Lancet. - 2008. - Vol. 372, № 9644. - P. 1174-1183.

64.

65. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction // Circulation. - 1999. - Vol. 100, № 4. - P. 376-380.

66.

67. Pizzetti F., Turazza F.M., Franzosi M.G. et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data // Heart. - 2001. - Vol. 86, № 5. - P. 527-532.

68.

69. Vermes E., Tardif J.C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials // Circulation. - 2003. - Vol. 107, № 23. - P. 2926-2931.

70.

71. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program // Am. Heart J. - 2006. - Vol. 152, № 1. - P. 86-92.

72.

73. Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. - 2005. - Vol. 149, № 3. - P. 548-557.

74.

75. Van Den Berg M.P., Crijns H.J., Van Veldhuisen D.J. et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation // J. Card. Fail. - 1995. - Vol. 1, № 5. - P. 355-363.

76.

77. Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study // Circulation. - 2002. - Vol. 106, № 3. - P. 331-336.

78.

79. Ueng K.C., Tsai T.P., Yu W.C. et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study // Eur. Heart J. - 2003. - Vol. 24, № 23. - P. 2090-2098.

80.

81. Madrid A.H., Marin I.M., Cervantes C.E. et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers // J. Renin Angiotensin Aldosterone Syst. - 2004. - Vol. 5, № 3. - P. 114-120.

82.

83. Grecu M., Olteanu R.O., Olteanu S.S., Georgescu C.A. Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion? // Rom. J. Intern. Med. - 2007. - Vol. 45, № 1. - P. 29-33.

84.

85. Tveit A., Grundvold I., Olufsen M. et al. Candesartan in the prevention of relapsing atrial fibrillation // Int. J. Cardiol. - 2007. - Vol. 120, № 1. - P. 85-91.

86.

87. Belluzzi F., Sernesi L., Preti P. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients // J. Am. Coll. Cardiol. - 2009. - Vol. 53, № 1. - P. 24-29.

88.

89. Disertori M., Latini R., Barlera S. et al. Valsartan for prevention of recurrent atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 360, № 16. - P. 1606-1617.

90.

91. Yin Y., Dalal D., Liu Z., et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation // Eur. Heart J. - 2006. - Vol. 27, № 15. - P. 1841-1846.

92.

93. Fogari R., Mugellini A., Destro M. et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients // J. Cardiovasc. Pharmacol. - 2006. - Vol. 47, № 1. - P. 46-50.

94.

95. Fogari R., Derosa G., Ferrari I. et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation // Am. J. Hypertens. - 2008. - Vol. 21, № 9. - P. 1034-1039.

96.

97. Fogari R., Zoppi A., Mugellini A. et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus // J. Cardiovasc. Pharmacol. - 2008. - Vol. 51, № 3. - P. 217-222.

98.

99. Goette A. Angiotensin II-antagonist in paroxismal atrial fibrillation. ANTIPAF-Trial. Hot Line III Session 708009, August 31st, 2010, ESC Congress, Stockholm.

100.


Для цитирования:


Новикова Т.Н. Илья Клейнер «Портрет Иосифа Бродского». Факторы риска развития фибрилляции предсердий. Современные подходы к лечению. Артериальная гипертензия. 2010;16(4):423-428. https://doi.org/10.18705/1607-419X-2010-16-4-423-428

For citation:


Novikova T.N. Ilya Kleiner «The Portrait of Iosif Brodsky». Risk factors for atrial fibrillation: Modern views on treatment. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(4):423-428. (In Russ.) https://doi.org/10.18705/1607-419X-2010-16-4-423-428

Просмотров: 128


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)